Cargando…

Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis

The genetic features of primary lymphoepithelioma‐like carcinoma (LELC) of the upper urinary tract have not been systematically explored. In this study, tumor mutation profiling was performed using whole‐genome sequencing in two patients with LELC of the renal pelvis. Novel candidate variants releva...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Bo, Huang, Yuanbin, Zhang, Hongshuo, Chen, Tingyu, Tao, Shenghua, Wang, Xiaogang, Wen, Shuang, Wang, Honglong, Lin, Zhe, Liu, Tianqing, Zhang, Hongxian, He, Tao, Li, Xiancheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580896/
https://www.ncbi.nlm.nih.gov/pubmed/36052737
http://dx.doi.org/10.1002/1878-0261.13307
_version_ 1784812495711502336
author Fan, Bo
Huang, Yuanbin
Zhang, Hongshuo
Chen, Tingyu
Tao, Shenghua
Wang, Xiaogang
Wen, Shuang
Wang, Honglong
Lin, Zhe
Liu, Tianqing
Zhang, Hongxian
He, Tao
Li, Xiancheng
author_facet Fan, Bo
Huang, Yuanbin
Zhang, Hongshuo
Chen, Tingyu
Tao, Shenghua
Wang, Xiaogang
Wen, Shuang
Wang, Honglong
Lin, Zhe
Liu, Tianqing
Zhang, Hongxian
He, Tao
Li, Xiancheng
author_sort Fan, Bo
collection PubMed
description The genetic features of primary lymphoepithelioma‐like carcinoma (LELC) of the upper urinary tract have not been systematically explored. In this study, tumor mutation profiling was performed using whole‐genome sequencing in two patients with LELC of the renal pelvis. Novel candidate variants relevant to known disease genes were selected using rare‐variant burden analysis. Subsequently, a population‐based study was performed using the Surveillance, Epidemiology, and End Results (SEER), PubMed, MEDLINE, Embase, and Scopus databases to explore clinical features and prognostic risk factors. Immunohistochemical analysis revealed seven positive cytokeratin‐associated markers in tumor cells and five positive lymphocyte‐associated markers in and around the tumor area. Sub‐sequently, we identified KDM6A as the susceptibility gene and LEPR as the driver gene by Sanger sequencing in case 2 of LELC of the renal pelvis. Three mutation sites of the existing targeted drugs were screened: CA9, a therapeutic target for zonisamide; ARVCF, a therapeutic target for bupropion; and PLOD3, a therapeutic target for vitamin C. In a population‐based study, patients with primary LELC of the upper urinary tract had clinical outcomes similar to those of patients with primary upper urinary tract urothelial carcinoma (UUT‐UC) before and after propensity score matching at 1 : 5. Focal subtype was an independent prognostic factor for the overall survival of patients with LELC of the upper urinary tract. The carcinogenesis of primary LELC may be due to different genetic variations, including single‐nucleotide variants, insertion and deletions, structural variations, and repeat regions, which may provide the basis for clinical diagnosis and treatment. The prognosis of LELC in the upper urinary tract is similar to that of UUT‐UC. We suggest that the focal subtype can serve as a prognostic factor for LELC of the upper urinary tract; however, further studies are required to confirm this.
format Online
Article
Text
id pubmed-9580896
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95808962022-10-20 Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis Fan, Bo Huang, Yuanbin Zhang, Hongshuo Chen, Tingyu Tao, Shenghua Wang, Xiaogang Wen, Shuang Wang, Honglong Lin, Zhe Liu, Tianqing Zhang, Hongxian He, Tao Li, Xiancheng Mol Oncol Research Articles The genetic features of primary lymphoepithelioma‐like carcinoma (LELC) of the upper urinary tract have not been systematically explored. In this study, tumor mutation profiling was performed using whole‐genome sequencing in two patients with LELC of the renal pelvis. Novel candidate variants relevant to known disease genes were selected using rare‐variant burden analysis. Subsequently, a population‐based study was performed using the Surveillance, Epidemiology, and End Results (SEER), PubMed, MEDLINE, Embase, and Scopus databases to explore clinical features and prognostic risk factors. Immunohistochemical analysis revealed seven positive cytokeratin‐associated markers in tumor cells and five positive lymphocyte‐associated markers in and around the tumor area. Sub‐sequently, we identified KDM6A as the susceptibility gene and LEPR as the driver gene by Sanger sequencing in case 2 of LELC of the renal pelvis. Three mutation sites of the existing targeted drugs were screened: CA9, a therapeutic target for zonisamide; ARVCF, a therapeutic target for bupropion; and PLOD3, a therapeutic target for vitamin C. In a population‐based study, patients with primary LELC of the upper urinary tract had clinical outcomes similar to those of patients with primary upper urinary tract urothelial carcinoma (UUT‐UC) before and after propensity score matching at 1 : 5. Focal subtype was an independent prognostic factor for the overall survival of patients with LELC of the upper urinary tract. The carcinogenesis of primary LELC may be due to different genetic variations, including single‐nucleotide variants, insertion and deletions, structural variations, and repeat regions, which may provide the basis for clinical diagnosis and treatment. The prognosis of LELC in the upper urinary tract is similar to that of UUT‐UC. We suggest that the focal subtype can serve as a prognostic factor for LELC of the upper urinary tract; however, further studies are required to confirm this. John Wiley and Sons Inc. 2022-09-02 2022-10 /pmc/articles/PMC9580896/ /pubmed/36052737 http://dx.doi.org/10.1002/1878-0261.13307 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Fan, Bo
Huang, Yuanbin
Zhang, Hongshuo
Chen, Tingyu
Tao, Shenghua
Wang, Xiaogang
Wen, Shuang
Wang, Honglong
Lin, Zhe
Liu, Tianqing
Zhang, Hongxian
He, Tao
Li, Xiancheng
Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
title Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
title_full Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
title_fullStr Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
title_full_unstemmed Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
title_short Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
title_sort analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma‐like carcinoma of the renal pelvis
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580896/
https://www.ncbi.nlm.nih.gov/pubmed/36052737
http://dx.doi.org/10.1002/1878-0261.13307
work_keys_str_mv AT fanbo analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT huangyuanbin analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT zhanghongshuo analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT chentingyu analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT taoshenghua analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT wangxiaogang analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT wenshuang analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT wanghonglong analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT linzhe analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT liutianqing analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT zhanghongxian analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT hetao analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis
AT lixiancheng analysisofgeneticprofilingpathomicssignatureandprognosticfeaturesofprimarylymphoepitheliomalikecarcinomaoftherenalpelvis